Cornea - ARVO

More documents

Recommendations

Info

ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Corneacorrected genome-wide significance of p
ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Cornearisks patients, and relatively low complications in high risk patients.Late HSV/VZV stromal inflammation can affect flap integrity.Commercial Relationships: Heidrun Gollogly, None; LeoMaguire, NoneSupport: Research to Prevent Blindness, Mayo FoundationProgram Number: 5420 Poster Board Number: A0119Presentation Time: 8:30 AM - 10:15 AMCharacterization of patients with ocular chronic graft-versushostdisease and evaluation of a new grading scaleChristiane Blecha 1 , Daniel Wolff 2 , David A. Maerker 1 , Horst Helbig 1 ,Tina Dietrich-Ntoukas 1 . 1 Ophthalmology, University HospitalRegensburg, Regensburg, Germany; 2 Hematology and Oncology,University Hospital Regensburg, Regensburg, Germany.Purpose: Ocular chronic graft-versus-host disease (cGVHD) is oneof the most frequent complications after allogeneic hematopoieticstem cell transplantation (alloHSCT). It often leads to reduced qualityof life due to severe ocular discomfort or even vision loss in severecases. Purpose of the study was to characterize patients with ocularcGVHD.Methods: All patients with ocular symptoms in the HSCT clinicwere examined ophthalmologically. Complete ocular examinationwas performed and subjective symptoms of keratoconjunctivitis sicca(KCS) assessed. Diagnosis of cGVHD was based on the NIHconsensus criteria for cGVHD. A new grading scale was applied,which was proposed by the Consensus Conference on ClinicalPractice in cGVHD (Dietrich-Ntoukas et al., 2011). Statisticalanalyses were performed using SPSS Version 20 (IBM SPSS,Armonk, NY, USA).Results: 35 patients (male n=25, female n=10, mean age 50 years)with ocular cGVHD were included. 95% of the patients suffered froma cGVHD of other organs, mostly of oral mucosa (62%) and the skin(62%). 94% of the patients showed blepharitis, 91% conjunctivalmanifestations. 71% suffered from corneal involvement (punctatekeratopathy (97%), filamentary keratitis (26%), corneal scarring(23%), corneal erosion (17%), corneal ulcer (12%)). The new gradingscale revealed inflammatory activity in all patients (mild (26%),moderate (43%) or severe (31%)). Results of the NIH scoring system:0% score 0 (no symptoms); 0% score 1 (mild symptoms of dry eye orasymptomatic signs of KCS); 43% score 2 (moderate dry eyesymptoms partially affecting activities of daily living, requiring drops> 3x per day or punctual plugs, without vision impairment); 57%score 3 (severe dry eye symptoms significantly affecting dailyactivities or loss of vision because of KCS). All 35 patients usedartificial tears, 29 used topical cyclosporine and 7 autologous serumeye drops.Conclusions: Patients with ocular cGVHD frequently have severeocular surface disease based on impaired function of the lacrimalgland but also of the conjunctiva and the lids, mostly associated withongoing inflammatory activity. The latter is currently not covered bythe NIH grading. Ophthalmological assessment of patients afteralloHSCT including lids, conjunctiva and inflammatory activity isnecessary to confirm the diagnosis, to optimize the therapy and toprevent irreversible complications.Commercial Relationships: Christiane Blecha, None; DanielWolff, None; David A. Maerker, None; Horst Helbig, None; TinaDietrich-Ntoukas, NoneProgram Number: 5421 Poster Board Number: A0120Presentation Time: 8:30 AM - 10:15 AMProliferative Gain of Function of Stromal Fibroblasts via SDF-1in Pathogenesis of PterygiaKyoung Woo Kim, Soo Hyun Park, Jae Chan Kim. Department ofOphthalmology, Chung-Ang University Hospital, Seoul, Republic ofKorea.Purpose: Biochemical signaling via Stromal cell-derived factor 1(SDF-1) and its receptor, Chemokine receptor type 4 (CXCR4) hadinitially attracted attention as a recruiter of progenitor cells to woundfor organ repair. Paradoxically, however, SDF-1/CXCR4 signaling isimplicated in proliferation and pheno-transdifferentiation offibroblasts in tumor. With viewing pterygia as exaggerated woundand mimicry of tumor, we investigate the involvement of SDF-1expression in pathogenesis of pterygia.Methods: In cultured stromal fibroblasts of pterygia (74 eyes) andnormal conjunctiva (24 eyes), the expression patterns of SDF-1 andCXCR4 were analyzed according to normal or pterygium, recurrencyand grade based on pterygial body morphology (T1-T3) orvascularity (V1-V3). To reveal the SDF-1-triggered possible phenotransdifferentiationof pterygial fibroblasts, the expression of α-SMA,which is the marker of myofibroblasts was co-analyzed paired withSDF-1. Then, the expression level of α-SMA was determined afterdownregulation of SDF-1 in fibroblasts by siRNA. The mRNAexpression was evaluated by RT-PCR, and the proteins were detectedby Western blot analysis, immunohisto- and immunocytochemistry.Results: Expression of SDF-1 was significantly higher in recurrent,T3 or V3 grade pterygia at both mRNA and protein levels. However,there was no significant difference in CXCR4 expression. Inimmunohistochemistry, SDF-1 was highly expressed at the stromallayer in recurrent or T3 pterygia, and at perivascular area especiallyin V3 pterygia. Expression of SDF-1 was positively correlated withthat of CXCR4 or α-SMA. Furthermore, the siRNA-SDF-1 reducedthe expression level of α-SMA.Conclusions: Proliferative gain of function of pterygial fibroblast viaSDF-1 expression is possibly associated with pathogenesis ofpterygia, especially in determination of recurrence, stromal fleshnessand vascularity. This suggests that SDF-1 can be an attractive newtherapeutic target to stabilize pterygia proliferation.Commercial Relationships: Kyoung Woo Kim, None; Soo HyunPark, None; Jae Chan Kim, NoneProgram Number: 5422 Poster Board Number: A0121Presentation Time: 8:30 AM - 10:15 AMBehaviour of Conjunctival Goblet Cells after allogenicHematopoietic Stem Cell TransplantationAlexandra B. Knoll 1 , Eva Jakob 1 , Karin Brandauer 1 , Bianca C.Dobner 1 , Ute Hegenbart 3 , Peter Dreger 3 , Gerd Auffarth 2 , FriederikeMackensen 1 . 1 Interdisciplinary Uveitis Center, University HospitalHeidelberg, Heidelberg, Germany; 2 Ophthalmology, UniversityHospital Heidelberg, Heidelberg, Germany; 3 Heamatology,University Hospital Heidelberg, Heidelberg, Germany.Purpose: The ocular Graft-versus-Host-Disease (oGvHD) is afrequent sequelae after hematopoietic stem cell transplantation(HSCT). We hypothesized that a decrease of goblet cells in theconjunctival epithelium can serve as predictive marker for anemerging oGvHD. To assess goblet cell density we compared themore invasive impression cytology (IC) with the less invasive in vivoconfocal microscopy (IVCM) (Figure A,B).Methods: Patients who were listed for HSCT were examined beforeand 100 days after the transplantation. The examination included aquestionnaire, slit lamp examination, Schirmer Test II, impressioncytology and confocal microscopy of the conjunctiva with theHeidelberg Retina Tomograph with the Rostock Cornea Modulattachment (HRT-RCM). At least three specimen/pictures of eachpatient were assessed for goblet cell density and means werecalculated. The Approval of the Ethical Review Board Heidelberg©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the ARVO Office at arvo@arvo.org.
Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
Page 4 and 5:
Page 6 and 7:
Page 8 and 9:
Page 10:
Page 13 and 14:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279: ARVO 2013 Annual Meeting Abstracts
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
show all

Cornea - ARVO

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?